This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Alimera Sciences, Inc.
Drug Names(s): Medidur FA, fluocinolone acetonide
Description: Iluvien is an injectable, non-erodable, intravitreal implant for the treatment of diabetic macular edema. Iluvien is designed to release the corticosteroid fluocinolone acetonide (FA) for up to three years. Importantly, the device is small enough to be injected into the back of the eye with a 25 gauge needle creating a self-sealing hole. This insertion procedure is very similar to an intravitreal injection and can be done in a doctor's office.
Medidur was originally developed by pSivida.
Alimera and pSivida
In February 2005, pSivida licensed to Alimera the rights to develop, market and sell Medidur.
In March 2008, pSivida announced that it amended its licensing agreement with development partner, Alimera Sciences, to reduce its share in the future profits of Medidur FA from 50% to 20% in return for consideration of up to approximately US$78m from Alimera.
pSivida granted Alimera an exclusive worldwide license to manufacture and sell ILUVIEN for the treatment and prevention of eye diseases in humans other than uveitis. Alimera agreed to fund all development costs, pay pSivida a $25.0 million milestone payment upon FDA approval of ILUVIEN and 20% of any net profits, as defined, on sales of ILUVIEN by Alimera.
Flextronics and Alimera
In March 2012, Alimera Sciences entered into a Manufacturing Services Agreement with Flextronics Medical Sales and Marketing. Under the...See full deal structure in Biomedtracker
Partners: pSivida Corporation Specialised Therapeutics Australia Pty, Ltd. Knight Therapeutics Inc. Societa Industria Farmaceutica Italiana S.p.A.
Additional information available to subscribers only: